CCL11 and metabolic dysfunction-associated steatohepatitis: In line with these observations, orally administered anti-eotaxin-1 monoclonal antibodies have shown to be able to alleviate immune-mediated hepatitis in mice, suggesting that eotaxin-1 may also be of interest to target in non-alcoholic steatohepatitis (NASH) [44].